Venlafaxine in adults with attention-deficit/hyperactivity disorder: An open clinical trial

Journal of Clinical Psychiatry

Volumn 57, Issue 5, 1996, Pages 184-189

  Findling, Robert L ^a   Schwartz, Michael A ^a   Flannery, Daniel J ^a   Manos, Michael J ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VENLAFAXINE;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MINIMAL BRAIN DYSFUNCTION; NERVOUSNESS; PRIORITY JOURNAL; RATING SCALE; SEXUAL DYSFUNCTION; SYMPTOMATOLOGY; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CYCLOHEXANOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0029891154     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993;150:1792-1798
3. Weiss G, Hechtman L, Milroy T, et al. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985;24:211-220
4. Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;50:565-576
5. Wender PH, Wood DR, Reimherr FW. Pharmacological treatment of attention deficit disorder, residual type (ADD, RT, "minimal brain dysfunction," "hyperactivity") in adults. Psychopharmacol Bull 1985;21:222-231
6. Wender PH, Reimherr FW, Wood D, et al. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985;142:547-552
7. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147:1018-1020
8. Mann HB, Greenspan SI. The identification and treatment of adult brain dysfunction. Am J Psychiatry 1976;133:1013-1017
9. Spencer T, Wilens T, Biederman J, et al. A double-blind crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-443
10. Wilens T, Biederman J, Mick E, et al. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995;183:48-50
11. Schweizer E, Clary C, Weise C, et al. An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant. Psychopharmacol Bull 1988; 24:195-197
12. Khan A, Fabre LF, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991;27:141-144
13. Schweizer E, Weise C, Clary C, et al. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-236
14. Goldberg HL, Finnerty R. An open-label, variable-dose study of WY-45,030 (venlafaxine) in depressed outpatients. Psychopharmacol Bull 1988;24:198-199
15. Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-1081
16. Shrivastava RK, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994;14:322-329
17. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo controlled study of desipramine in the treatment of ADD, I: efficacy. J Am Acad Child Adolesc Psychiatry 1989;28:777-784
18. Wilens TE, Biederman J, Geist DE, et al. Nortriptyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 1993;32:343-349
19. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo-controlled study of desipramine in the treatment of ADD, III: lack of impact of comorbidity and family history factors on clinical response. J Am Acad Child Adolesc Psychiatry 1993;32:199-204
20. Zajecka JM, Ross JS. Management of comorbid anxiety and depression. J Clin Psychiatry 1995;56(suppl 2):10-13
21. Zajecka JM, Fawcett J, Guy C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine [letter]. J Clin Psychopharmacol 1990;10:152-153
22. Venlafaxine (Effexor). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1996:2719-2723
23. DuPaul GJ. Parent and teacher ratings of ADHD symptoms: psychometric properties in a community-based sample. Journal of Clinical Child Psychology 1991;20:245-253
24. National Institute of Mental Health. Clinical Global Impressions (CGI) scale. Psychopharmacol Bull 1985;21:839-843
25. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
27. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993;150:885-890
28. Adler LA, Resnick S, Kunz M, et al. Open label trial of venlafaxine (Effexor) in attention deficit disorder. Presented at the 35th New Clinical Drug Evaluation Unit meeting; June 1, 1995; Orlando, Fla
29. Hornig-Rohan M, Amsterdam JD. Venlafaxine vs stimulant therapy in patients with dual diagnoses of attention deficit disorder and depression. Presented at the 35th New Clinical Drug Evaluation Unit meeting; June 1, 1995; Orlando, Fla
30. Wilens TE, Biederman J, Spencer TJ. Venlafaxine for adult ADHD [letter]. Am J Psychiatry 1995;152:1099-1100
31. Klein RG, Wender P. The role of methylphenidate in psychiatry. Arch Gen Psychiatry 1995;52:429-433
32. Reimherr FW, Hedges DW, Strong RE, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Presented at the 35th New Clinical Drug Evaluation Unit meeting; June 1, 1995; Orlando, Fla
33. Schubiner H, Tzelepis A, Isaacson JH, et al. The dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review. J Clin Psychiatry 1995;56:146-150
34. Zametkin AJ. Attention-deficit disorder: born to be hyperactive? JAMA 1995;273:1871-1874
35. Lowe TL, Cohen DJ, Detlor J, et al. Stimulant medications precipitate Tourette's syndrome. JAMA 1982;247:1729-1731